Clinical Outcomes and Validation of Ursodeoxycholic Acid Response Scores in Patients with Korean Primary Biliary Cholangitis: A Multicenter Cohort Study
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: The ursodeoxycholic acid (UDCA) response score (URS) was developed to identify poor responders to UDCA before treatment, in order to offer timely and proactive intervention. However, validation of the URS in Asian population is warranted. Methods: A total of 173 Asian patients diagnosed with primary biliary cholangitis (PBC) between 2007 and 2016 at seven academic institutions in Korea who started UDCA treatment were analyzed to validate the performance of URS. UDCA response was defined as an alkaline phosphatase level less than 1.67 times the upper limit of normal after 1-year of UDCA treatment. In addition, prognostic performance of URS for liver-related events, defined as newly developed hepatic decompensation or hepatocellular carcinoma was evaluated. Results: After 1 year of UDCA treatment, 133 patients (76.9%) achieved UDCA response. UDCA response rate was 98.7% for those with URS ≥1.41 (n=76) and 58.8% for those with URS <1.41 (n=97). The area under the receiver operating characteristic curve of URS in predicting UDCA response was 0.84 (95% confidence interval, 0.78 to 0.88). During a median follow-up of 6.5 years, liver-related events developed in 18 patients (10.4%). Among 117 patients with PBC stage I-III by histological evaluation, the 5-year liver-related event-free survival rate differed according to the URS; 100% for URS ≥1.41 and 86.5% for URS <1.41 (p=0.005). Conclusions: URS demonstrated good performance in predicting a UDCA treatment response in Asian PBC patients. In addition, the risk of liver-related events differed according to the URS for the PBC stage. Thus, URS can be used to predict the response and clinical outcome in patients with PBC.
Abstract
Background/Aims: The ursodeoxycholic acid (UDCA) response score (URS) was developed to identify poor responders to UDCA before treatment, in order to offer timely and proactive intervention. However, validation of the URS in Asian population is warranted. Methods: A total of 173 Asian patients diagnosed with primary biliary cholangitis (PBC) between 2007 and 2016 at seven academic institutions in Korea who started UDCA treatment were analyzed to validate the performance of URS. UDCA response was defined as an alkaline phosphatase level less than 1.67 times the upper limit of normal after 1-year of UDCA treatment. In addition, prognostic performance of URS for liver-related events, defined as newly developed hepatic decompensation or hepatocellular carcinoma was evaluated. Results: After 1 year of UDCA treatment, 133 patients (76.9%) achieved UDCA response. UDCA response rate was 98.7% for those with URS ≥1.41 (n=76) and 58.8% for those with URS <1.41 (n=97). The area under the receiver operating characteristic curve of URS in predicting UDCA response was 0.84 (95% confidence interval, 0.78 to 0.88). During a median follow-up of 6.5 years, liver-related events developed in 18 patients (10.4%). Among 117 patients with PBC stage I-III by histological evaluation, the 5-year liver-related event-free survival rate differed according to the URS; 100% for URS ≥1.41 and 86.5% for URS <1.41 (p=0.005). Conclusions: URS demonstrated good performance in predicting a UDCA treatment response in Asian PBC patients. In addition, the risk of liver-related events differed according to the URS for the PBC stage. Thus, URS can be used to predict the response and clinical outcome in patients with PBC.
참고문헌 (25)
- European Association for the Study of the Liver, "EASL clinical practice guidelines : the diagnosis and management of patients with primary biliary cholangitis", J Hepatol, 67, pp.145~172 (2017)
- Lindor KD, "Primary biliary cholangitis : 2018 practice guidance from the American Association for the Study of Liver Diseases", Hepatology, 69, pp.394~419 (2019)
- Shah RA, "Current and potential treatments for primary biliary cholangitis", Lancet Gastroenterol Hepatol, 5, pp.306~315 (2020)
- Liang Y, "Primary biliary cirrhosis and cancer risk : a systematic review and meta-analysis", Hepatology, 56, pp.1409~1417 (2012)
- Zein CO, "When is liver biopsy needed in the diagnosis of primary biliary cirrhosis?", Clin Gastroenterol Hepatol, 1, pp.89~95 (2003)
- Murillo Perez CF, "Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response", Aliment Pharmacol Ther, 50, pp.1127~1136 (2019)
- Tan D, "Liver biopsy in primary biliary cholangitis : indications and interpretation", Clin Liver Dis, 22, pp.579~588 (2018)
- Harms MH, "Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis", J Hepatol, 71, pp.357~365 (2019)
- Corpechot C, "The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis", Hepatology, 32, pp.1196~1199 (2000)
- Parés A, "Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid", Gastroenterology, 130, pp.715~720 (2006)
- Carbone M, "The UK-PBC risk scores : derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis", Hepatology, 63, pp.930~950 (2016)
- Cheung AC, "External validation of the United Kingdom-primary biliary cholangitis risk scores of patients with primary biliary cholangitis treated with ursodeoxycholic acid", Hepatol Commun, 2, pp.676~682 (2018)
- Lammers WJ, "Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy", Gastroenterology, 149, pp.1804~1812 (2015)
- Carbone M, "Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis : development and validation of the UDCA Response Score", Lancet Gastroenterol Hepatol, 3, pp.626~634 (2018)
- Kumagi T, "Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis", Am J Gastroenterol, 105, pp.2186~2194 (2010)
- Momah N, "Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis", Liver Int, 32, pp.790~795 (2012)
- Yagi M, "A validation study of the ursodeoxycholic acid response score in Japanese patients with primary biliary cholangitis", Liver Int, 40, pp.1926~1933 (2020)
- Zhang LN, "Early biochemical response to ursodeoxycholic acid and long-term prognosis of primary biliary cirrhosis : results of a 14-year cohort study", Hepatology, 58, pp.264~272 (2013)
- Lammers WJ, "Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis : an international follow-up study", Gastroenterology, 147, pp.1338~1349 (2014)
- Corpechot C, "Early primary biliary cirrhosis : biochemical response to treatment and prediction of long-term outcome", J Hepatol, 55, pp.1361~1367 (2011)
- Corpechot C, "Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis", Hepatology, 48, pp.871~877 (2008)
- John BV, "Ursodeoxycholic acid response is associated with reduced mortality in primary biliary cholangitis with compensated cirrhosis", Am J Gastroenterol, 116, pp.1913~1923 (2021)
- Kuiper EM, "Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid", Gastroenterology, 136, pp.1281~1287 (2009)
- Poupon RE, "Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis", J Hepatol, 39, pp.12~16 (2003)
- Kawata K, "The ursodeoxycholic acid response score predicts pathological features in primary biliary cholangitis", Hepatol Res, 51, pp.80~89 (2021)